NXP900
Advanced solid tumors
Key Facts
About Nuvectis Pharma
Nuvectis Pharma is a publicly traded, clinical-stage biotech focused on targeted cancer therapies. Its lead assets are NXP900, a unique Type 1.5 SRC/YES1 inhibitor advancing into Phase 1b trials, and NXP800, a GCN2 activator being explored in ARID1a-mutated ovarian cancer and cholangiocarcinoma. The company is led by a seasoned management team with prior successful drug development and commercialization experience.
View full company profileAbout Nuvectis Pharma
Nuvectis Pharma is a publicly traded, clinical-stage biotech focused on targeted cancer therapies. Its lead assets are NXP900, a unique Type 1.5 SRC/YES1 inhibitor advancing into Phase 1b trials, and NXP800, a GCN2 activator being explored in ARID1a-mutated ovarian cancer and cholangiocarcinoma. The company is led by a seasoned management team with prior successful drug development and commercialization experience.
View full company profileTherapeutic Areas
Other Advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |